Jun. 30 at 7:07 PM
⌛️⏳️ Potential swing ideas 💡💡
✅️
$ATPC Company focuses on health and wellness products, renewable energy and sustainability initiatives, previously entered collaboration with Citadel Investment for opportunities in Oil, gas, and petroleum products
✅️
$CRDL recently announced positive phase II ARCHER Trial data for CardioIRx, recently secured USA patent for hear drugs, company focuses on novel anti-inflammatory and anti-fibrotic therapies for heart disease, its lead drug, CardioIRx (an oral cannabidiol formulation) is designed to treat serious cardiac conditions like acute myocarditis and recurrent pericarditis by modulating inflammatory pathways involved in fibrosis and heart damage. First Berlin Equity Research price target
$7.50, Canaccord Genuity buy rating, HC Wainwright price target
$9, does have mixed shelf